The FDA identified six cases supporting a plausible association between GnRH agonist use and pseudotumor cerebri. Five were undergoing treatment for central precocious puberty and one for transgender care.

Officials provides updates on resources to aid schools and available therapeutics designed to treat COVID-19 patients.

Both products contain two direct-acting antiviral drugs that provide a complete regimen for treatment of chronic hepatitis C virus infection.

Medication nonadherence is a problem across pediatric chronic diseases, even those that can be life-threatening.

AAP resource provides answers on use of outpatient monoclonal antibody therapy for COVID-19.

Recommendations for use of treatments in children are extrapolated from adult data. Clinical trials are needed to demonstrate benefit in pediatric patients.

Emergency use authorization allows the use of unapproved medical products or the unapproved use of approved medical products during a public health emergency. Manufacturers must demonstrate that the therapy’s known and potential benefits outweigh its known and potential risks.

The U.S. government recently released a plan to change the trajectory of antibiotic resistance and improve the health of all Americans.

Partnerships help ensure that children’s therapeutic needs are addressed without exposing pediatric patients to unnecessary clinical trials.

CDC’s Up and Away and Out of Sight educational campaign aligns with AAP efforts to promote pediatrician counseling of parents on how to store medications safely.

The first generic albuterol sulfate (Proventil HFA) metered-dose inhaler, 90 mcg/inhalation has been approved by the Food and Drug Administration (FDA) for patients ages 4 years and older.